Cabaletta Bio Company
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Technology:
CAR-T
Industry:
Biotechnology, Health Care, Medical, Public, Robotics, Therapeutics
Headquarters:
Philadelphia, Pennsylvania, United States
Founded Date:
2017-06-01
Employees Number:
1-10
Funding Status:
IPO
Investors Number:
8
Total Funding:
88000000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2019-01-03
Last Funding Type:
Series B
Register and Claim Ownership